Overcoming autologous cell therapy logistics challenges in the age of COVID-19

Experienced team for managed logistics is key

Subscribe

Get updates from the Cell Lines Blog delivered to your inbox.

Can cell therapies unlock the COVID-19 mystery?

The promise of MSC therapies to treat deadly manifestations of cytokine storms

How COVID-19 is changing the production of cell therapies

Implementation of contingency plans allows for continued progress in therapy development

Managing donor collections during the COVID-19 pandemic

Why a diverse apheresis center network is critical to business continuity

Are ‘super donors’ the answer to sustainable growth for the allogeneic cell and gene therapy industry?

Why reliance on a small subset of donors could introduce risk for companies

Navigating a time-sensitive cell therapy supply chain during the coronavirus outbreak (Updated)

Why established systems and relationships matter

HLA matching could bring more allogeneic cell therapies to market, faster

An expert opinion on HLA matching relevance for allogeneic cell therapies

Advancements in Cell and Gene Therapy: 2019 Year-in-Review

Quality Starting Material: The Driving Force Behind Life-Saving Cell Therapies

By Jamie Margolis, PhD, Senior Vice President of Donor Services, NMDP/Be The Match